ArticleFrontiers in endocrinology2026
Association of HDL2b with chronic kidney disease in type 2 diabetes mellitus populations.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Diabetic kidney disease (DKD) is a major microvascular complication of type 2 diabetes mellitus (T2DM). High-density lipoprotein cholesterol (HDL-C) has traditionally been considered renoprotective, yet growing evidence suggests that HDL subclasses may differ in biological function. This study aimed to investigate the association between HDL subclasses, particularly HDL2b, and chronic kidney disease (CKD) in Chinese adults with T2DM. Methods: In this cross-sectional study, patients with T2DM were enrolled. CKD was defined as urinary albumin-to-creatinine ratio (UACR) ≥3.0 mg/mmol and/or estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m². HDL subclasses were measured using capillary electrophoresis-based microfluidics. Participants were categorized into quartiles of HDL-C, HDL2b, and HDL3. Multivariable logistic regression models were constructed with progressive adjustment for anthropometric indices, hypertension, insulin resistance (HOMA-IR), and inflammatory markers. Results: Among 481 patients with T2DM, 136 (28.3%) had CKD. Patients with CKD exhibited significantly lower HDL2b levels (P = 0.001), together with greater insulin resistance and systemic inflammation (all P<0.05). HDL2b showed stronger inverse correlations than total HDL-C with adiposity, glycemic indices, insulin resistance, and inflammatory markers (all P<0.05). In multivariable logistic regression, higher HDL2b was independently associated with a lower risk of CKD. Compared with the lowest quartile, the third and fourth quartiles were associated with reduced odds of CKD (Q3: OR = 0.425, 95% CI 0.220-0.821, P = 0.012; Q4: OR = 0.367, 95% CI 0.188-0.717, P = 0.001). The inverse association between HDL2b and CKD was stronger in participants with higher insulin resistance (P for interaction=0.044). Conclusion: Higher HDL2b, but not total HDL-C or HDL3, is independently associated with lower risk of CKD in T2DM. HDL2b may serve as a sensitive biomarker for early renal risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.